【剂型】片剂 注射液 口服糖浆剂
VIMPAT INJECTION
Generic Name for VIMPAT INJECTION
Lacosamide 10mg/mL; soln for IV infusion.
Legal Classification:
CV
Pharmacological Class for VIMPAT INJECTION
Sodium channel inactivator.
Manufacturer of VIMPAT INJECTION
UCB Inc.
Indications for VIMPAT INJECTION
Adjunct in partial-onset seizures, when oral administration is not feasible.
Adult dose for VIMPAT INJECTION
Oral soln: use calibrated measuring device. Inj: may give without diluting, or mix in appropriate diluent and give by IV infusion over 30–60min. For oral and inj: ≥17yrs: initially 50mg twice daily; may increase at weekly intervals by 100mg/day in 2 divided doses . Maintenance dose: 200–400mg/day. Renal impairment (CrCl≤30mL/min), ESRD, mild-moderate hepatic impairment: max 300mg/day. Consider supplemental dose (50%) after hemodialysis. Avoid abrupt cessation (withdraw over 1 week).
Children's dosing for VIMPAT INJECTION
<17yrs: not recommended.
Also:
VIMPAT
VIMPAT ORAL SOLUTION
Warnings/Precautions for VIMPAT INJECTION
Severe hepatic impairment: not recommended. Cardiac conduction disturbances (eg, 2nd degree AV block). Severe cardiac disease (eg, myocardial ischemia, heart failure). Monitor for suicidal ideation, depression. Diabetic neuropathy. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
Interactions for VIMPAT INJECTION
Caution with other drugs that cause PR prolongation.
Adverse Reactions for VIMPAT INJECTION
Dizziness, ataxia, diplopia, headache, GI upset, syncope; rare: multiorgan hypersensitivity reaction.
How is VIMPAT INJECTION supplied?
Tabs—60
Oral soln—465mL
Single-use vials (20mL)—10